Trial Profile
A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in Which Peginterferon Lambda-1a (BMS-914143) Was Administered for the Treatment of Chronic Hepatitis C
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2016
Price :
$35
*
At a glance
- Drugs Peginterferon lambda-1a (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 25 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 10 Oct 2013 New source identified and integrated (Mayo Clinic).
- 28 Apr 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2011-005293-31).